诺比丁:一种潜在的红色素受体激活剂,可以保护细胞免受缺氧作用
Na Liu1, Yuzhuo Sun1, Jieyun Liu1
1Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, China.
Apoptosis : an international journal on programmed cell death
|January 4, 2025
概括
在果皮中发现的nobiletin,充当了红素受体 (EPOR) 激活剂. 它通过激活EPOR信号通路来保护细胞免受缺氧,为脏疾病提供潜在的治疗益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 脏生理学 脏生理学
背景情况:
- 皮是一种传统的中国草药,具有多种药理学效果.
- 红素受体 (EPOR) 在脏组织中起着保护作用.
- 人们假设,皮化合物的潜力可以激活EPOR,从而产生对脏的益处.
研究的目的:
- 为了在果皮中识别EPOR向的化合物.
- 调查公告对EPOR的作用机制.
- 为了评估nobiletin在低氧条件下对细胞的保护作用.
主要方法:
- 开发了一个EPOR/细胞膜色谱-HPLC-MS系统用于化合物查.
- 利用正面分析,非线性染色学和分子对接来评估nobiletin-EPOR结合.
- 通过Ca2+调动,cAMP积累和JAK2/STAT5酸化来评估EPOR激活.
- 研究了nobiletin在由CoCl2.2诱导的缺氧下对人类质介质细胞 (HMC) 的影响.
- 分析了与亡相关的蛋白质,并使用siRNA和lentivirus操纵了EPOR表达.
主要成果:
- 诺比利被确定为EPOR/CMC列中保留的一种化合物.
- 诺比利证明了与EPOR具有显著的结合亲和力和特定的结合位点.
- 诺比林激活了EPOR下游信号,包括JAK2和STAT5酸化.
- 过度表达EPOR增强了细胞对低氧的耐受性.
- 诺比利丁通过促进增殖和抑制亡来保护HMC免受缺氧.
结论:
- 诺比是EPOR的潜在小分子激动剂.
- 诺比利丁通过EPOR激活保护人类球介质细胞免受缺氧.
- 这一发现表明nobiletin在脏保护方面具有治疗潜力.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Erythropoiesis
4.0K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
133
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
133
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135


